NCT07197450View on ClinicalTrials.gov

Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 20, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Hypoparathyroidism
Interventions
DRUG

intravenous administration of PTH1-84 mRNA

intravenous administration of PTH1-84 mRNA

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT07197450 - Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism | Biotech Hunter | Biotech Hunter